Wall Street analysts expect American Renal Associates Holdings, Inc (NYSE:ARA) to announce $196.15 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for American Renal Associates Holdings’ earnings, with the lowest sales estimate coming in at $195.30 million and the highest estimate coming in at $197.00 million. American Renal Associates Holdings posted sales of $192.96 million in the same quarter last year, which suggests a positive year-over-year growth rate of 1.7%. The firm is expected to issue its next earnings results on Thursday, November 9th.

On average, analysts expect that American Renal Associates Holdings will report full-year sales of $196.15 million for the current financial year, with estimates ranging from $758.90 million to $765.00 million. For the next year, analysts forecast that the business will report sales of $839.00 million per share, with estimates ranging from $834.00 million to $844.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for American Renal Associates Holdings.

American Renal Associates Holdings (NYSE:ARA) last announced its earnings results on Tuesday, August 8th. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.04. American Renal Associates Holdings had a negative net margin of 1.54% and a positive return on equity of 18.25%. The business had revenue of $185.99 million during the quarter, compared to the consensus estimate of $188.23 million. The company’s quarterly revenue was up .2% compared to the same quarter last year.

Separately, Zacks Investment Research raised shares of American Renal Associates Holdings from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $22.33.

Several institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its stake in shares of American Renal Associates Holdings by 19.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock worth $162,000 after acquiring an additional 1,443 shares in the last quarter. State Street Corp increased its stake in shares of American Renal Associates Holdings by 5.2% in the 2nd quarter. State Street Corp now owns 146,039 shares of the company’s stock worth $2,709,000 after acquiring an additional 7,244 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of American Renal Associates Holdings in the 2nd quarter worth about $230,000. Vanguard Group Inc. increased its stake in shares of American Renal Associates Holdings by 7.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,002,294 shares of the company’s stock worth $18,593,000 after acquiring an additional 73,526 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of American Renal Associates Holdings by 33.4% in the 2nd quarter. Northern Trust Corp now owns 143,693 shares of the company’s stock worth $2,666,000 after acquiring an additional 35,965 shares in the last quarter. Institutional investors own 89.92% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/13/american-renal-associates-holdings-inc-ara-expected-to-post-quarterly-sales-of-196-15-million-2.html.

American Renal Associates Holdings (NYSE ARA) opened at 12.87 on Friday. The company’s 50-day moving average is $14.67 and its 200-day moving average is $14.67. American Renal Associates Holdings has a 52 week low of $12.68 and a 52 week high of $24.94. The company’s market cap is $402.64 million.

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates Holdings (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates Holdings (NYSE:ARA)

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.